US equities |
MU $991.10 ▼-3.68% META $748.46 ▲+4.15% NVDA $226.37 ▼-1.27% SNDK $1,482.61 ▼-6.27% SPCX $163.85 ▲+0.79% AMD $590.25 ▼-2.94% MSFT $540.33 ▲+0.98% TSLA $379.00 ▼-0.97%
FinancialContent

Nutriband Inc. - Warrant (NQ:NTRBW)

0.5500 UNCHANGED
Last Price Updated: 3:59 PM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nutriband Inc. - Warrant

< Previous 1 2 3 4 5 6 Next >
News headline image
Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis
Sheridan joins independent journalist Nick Shirley to discuss how Nutriband's AVERSA™ abuse-deterrent technology is designed to help reduce the abuse, misuse, and accidental exposure driving the... 
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica
The Company recently announced an exclusive distribution agreement with Innomedica CCB S.A. for its Kinesiology Line, AVERSA products and Mosquito repellent patches 
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica
From Nutriband Inc.
Via GlobeNewswire
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) Highlights Board Appointments and AVERSA Fentanyl Milestones From Annual Meeting
Via Investor Brand Network
Topics Intellectual Property
News headline image
Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband CEO Publishes Letter to Shareholders
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration
The LOI Aligns with Federal Priorities on Fentanyl Crisis, Artificial Intelligence, and Quantum Technology 
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction
From Nutriband Inc.
Via GlobeNewswire
News headline image
REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
From Nutriband Inc.
Via GlobeNewswire
Nutriband Inc. (NASDAQ:NTRB) Targets the Opioid Safety Gap in a Multi-Billion-Dollar Market
Via AB Newswire
News headline image
Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband Co-Founder Gareth Sheridan Returns as CEO
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband To Present at the Noble Capital Markets’ Emerging Growth Virtual Equity Conference
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband Inc. to Present at the MicroCap Rodeo Conference
Thursday, September 25, 2025 in New York City 
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000
From Nutriband Inc.
Via GlobeNewswire
News headline image
Nutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025
Nutriband Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference 
From Nutriband Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >